B
Bull
Bull · 25%IMAB
$2.26
情境價格
$4.630
-0.010 (-0.22%)收盤時
Loading chart…
- High
- 4.770
- Open
- 4.700
- VWAP
- 4.63
- Vol
- 1.52M
- Mkt Cap
- 136.69M
- Low
- 4.490
- Amount
- 7.03M
- EV/EBITDA, TTM
- 0.81
I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.
估值指標
The current forward P/E ratio for I-Mab (IMAB) is -2.62, compared to its 5-year average forward P/E of -7.03.
Alphio AI Price Scenarios for IMAB
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding IMAB
事件時間軸
資訊
4.510-29GlobenewswireI-MAB Rebrands as NovaBridge Biosciences, Trading to Commence on October 30, 2025, Featuring New Brand and Logo to Highlight Strategic Shift to a Global Biotech Platform
4.010-24BenzingaBTIG Affirms Buy Rating for I-MAB, Keeps $9 Price Target Intact
7.010-23PRnewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
- 4.010-17Benzinga
BTIG Reaffirms Buy Rating for I-MAB, Increases Price Target to $9
2.010-10NASDAQ.COMI-Mab Sponsored ADR (IMAB) Sees 24.14% Weekly Increase: Key Information to Consider
IMAB FAQ — answered by Alphio AI
I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。